Related Experiment Video
Updated: Jun 6, 2026

Engineering Oncogenic Heterozygous Gain-of-Function Mutations in Human Hematopoietic Stem and Progenitor Cells
Published on: March 10, 2023
Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know
Orly Leiva1, Olivia C Liu2, Monica Ferrante1
1Gill Heart and Vascular Institute, University of Kentucky College of Medicine, Lexington, KY.
Abstract:
Patients with myeloproliferative neoplasms (MPNs), including essential thrombocythemia, polycythemia vera, and myelofibrosis, are at increased risk of cardiovascular disease and complications. The most recognized cardiovascular complications among patients with MPN are arterial and venous thrombotic events. However, mounting evidence suggest that nonthrombotic cardiovascular complications, including heart failure and pulmonary hypertension, are also common and are associated with adverse outcomes and overall prognosis. Therefore, it is important that hematologists become aware of such complications and are able to identify them as they arise. Additionally, cardiovascular disease treatment, including antithrombotic therapy and guideline-directed medical therapy for heart failure, may impact MPN-specific outcomes. Therefore, we review current literature of cardiovascular disease and complications among patients with MPNs and their impact on patient outcomes and prognosis.
Related Concept Videos
Cardiomyopathy VII: Pre and Post Operative Nursing Management
Hemodialysis II: Procedure and Complications
Bone Marrow Sampling and Transplants
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy the...
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Stem Cell Therapy for Tissue Regeneration
Types of Stem Cells used in Stem Cell Therapy
The two main cell types that...
Chronic Kidney Disease II: Clinical Manifestations

